Isotope (part of
Rosatom’s Research Division) and the Vinča Institute of Nuclear Sciences have
formally established a strategically important partnership by signing a
contract for the supply of radioactive isotopes.
The contract provides for the delivery of sealed gamma radiation sources based on isotopes iridium-192 (Ir-192) and selenium-75 (Se-75). These products play a crucial role in modern non-destructive testing methods, ensuring the highest standards of quality control and safety in critical industrial sectors.
The delivery of the first batch of sources will lay the foundation for long-term cooperation, supporting continuity in both research and operational activities at the Vinča Institute.
In addition to supply of new sources, the agreement will also provide the institute with direct access to advanced resources essential for the further development of nuclear science in the country. Deliveries will be carried out in strict accordance with international safety protocols, using specialized transport packaging and adhering to the highest environmental standards.
Beyond industrial applications, the partners also have experience in supplying molybdenum-99 (Mo-99), which is used in the production of technetium generators for medical diagnostics and supports the provision of radiopharmaceuticals to healthcare institutions.
"The signing of this contract confirms the mutual interest of the parties in developing long-term cooperation and will open new prospects for business expansion. We expect that the cooperation will not be limited to the supply of sources for industrial radiography and will be gradually expanded through new areas, including medical products," said Vladimir Fesenko, Sales Director at Isotope.
"This agreement underscores our commitment to strengthening international scientific cooperation and application of the advanced technological solutions. The partnership with our colleagues from Rosatom allows us to further improve the work of the Institute and provide a stable basis for the development of nuclear sciences in Serbia. We believe that this is just one of a series of steps that will contribute to long-term technological progress and strengthening of our research potential for the benefit of the entire society," said Prof. Dr. Slavko Dimovic, Director of the Vinča Institute of Nuclear Sciences.
Isotope (JSC All-Regional Association Isotope) is an
industry integrator for isotope production and distribution within Rosatom,
serving as the official supplier of isotope products to international markets
and a key distributor domestically. The company works with over 170 foreign
partners in 50 countries and around 700 organizations across Russia, including
medical institutions, industrial enterprises, and research centers. Rosatom
currently offers the world’s most extensive range of radioactive and stable
isotopes for medical use, handling up to 9,000 shipments annually, around 2,000
of which are exports.
The Vinča Institute of Nuclear Sciences (Institut za nuklearne nauke
"Vinča") based in Belgrade, was founded in 1948 as a
multidisciplinary research center specializing in physics, chemistry, and
biology.
Rosatom Scientific Division conducts innovative fundamental and applied research for the development of nuclear and non-nuclear technologies (including in the field of closing the nuclear fuel cycle, thermonuclear fusion, nuclear medicine); creates science-intensive technologies both for it and for other industries. It comprises 13 research institutes and commercial companies, including Scientific Production Association LUCH (JSC “NII NPO LUCH”), Research Institute of Technical Physics and Automation (JSC “NIITFA”), Giredmet (JSC “Giredmet”), V. G. Khlopin Radium Institute, and others. They have a developed research infrastructure, as well as their own pilot production, capable of fully implementing a scientific idea: from fundamental research to design developments and prototypes. Most of the division's research and development activities are carried out within the framework of the Unified Industry Thematic Plan. Its responsibilities also include testing, development of high-tech medical equipment, and creation of advanced structural materials. In addition, projects are underway to commercialize promising high-tech solutions.
